163210-97-7

Basic information

• Product Name: METHYL 4-(PIPERAZIN-1-YL)BENZOATE
• Synonyms: Methyl 4-(1-piperazinyl)benzoate;methyl 4-(1-piperazinyl)benzoate hydrochloride;methyl 4-piperazin-1-ylbenzoate(SALTDATA: 1.5HCl);Benzoic acid, 4-(1-piperazinyl)-, Methyl ester;4-Piperazin-1-yl-benzoic acid Methyl ester;METHYL 4-(PIPERAZIN-1-YL)BENZOATE
• CAS NO: 163210-97-7
• Molecular Formula: C₁₂H₁₆N₂O₂
• Molecular Weight: 220.27
• Product Categories: pharmacetical
• Mol File: 163210-97-7.mol
• Article Data: 15

Chemical Properties

• Melting Point: 104-105 °C
• Boiling Point: 377.057 °C at 760 mmHg
• Flash Point: 181.838 °C
• Appearance: /
• Density: 1.126 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.542
• PKA: 8.81±0.10(Predicted)
• CAS DataBase Reference: METHYL 4-(PIPERAZIN-1-YL)BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-(PIPERAZIN-1-YL)BENZOATE(163210-97-7)
• EPA Substance Registry System: METHYL 4-(PIPERAZIN-1-YL)BENZOATE(163210-97-7)

Safety Data

• Hazardous Substances Data: 163210-97-7(Hazardous Substances Data)

Usage

General Description

Methyl 4-(piperazin-1-yl)benzoate is a chemical compound that is commonly used in the pharmaceutical industry as a precursor for the synthesis of various pharmaceutical drugs. It is a derivative of benzoic acid and contains a piperazine moiety, which is a common structural feature in many pharmaceuticals. METHYL 4-(PIPERAZIN-1-YL)BENZOATE has been found to exhibit various pharmacological activities, such as being a potential anti-inflammatory and analgesic agent. It is known to interact with certain receptors in the body, particularly those involved in the central nervous system. Methyl 4-(piperazin-1-yl)benzoate is an important building block in the synthesis of many pharmaceutical compounds and may have potential therapeutic applications in the future.

InChI:InChI=1/C12H16N2O2/c1-16-12(15)10-2-4-11(5-3-10)14-8-6-13-7-9-14/h2-5,13H,6-9H2,1H3

Upstream product

• 158985-36-5 4-(4-methoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 619-45-4 4-methoxycarbonyl aniline 
• 68104-63-2 N-(4-cyanophenyl)piperazine 
• 110-85-0 piperazine 
• 403-33-8 methyl 4-flurobenzoate 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 3375-31-3 palladium diacetate 
• 865-48-5 sodium t-butanolate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 619-50-1 4-nitrobenzoic acid methyl ester 
• 334-22-5 N,N-bis(chloro-2-ethyl)amine 
• 619-44-3 methyl 4-iodobenzoate 

Downstream Products

• 158985-36-5 4-(4-methoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 354813-11-9 4-piperazin-1-yl-benzoic acid hydrochlorid 
• 354813-20-0 4-[4-(1-Propyl)-piperazin-1-yl]-benzoic acid methyl ester 
• 1374752-74-5 methyl 4-(4-(2-oxoindolin-5-ylsulfonyl)piperazin-1-yl)benzoate 
• 1447331-89-6 {6-[4-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}acetic acid 
• 1447330-19-9 [1-oxo-6-(4-piperazinium-1-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]acetic acid trifluoroacetate 
• 162046-66-4 4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzoic acid 
• 1447331-32-9 {6-[4-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}acetic acid methyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors

The synthesis and biological evaluation of a variety of 4-piperazinyl-containing Chidamide derivatives is described. Some of these compounds were shown to inhibit HDAC1 with IC50 values below micromolar range, and inhibited proliferation of sev

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αiIbβ3

A series of novel RGD mimetics containing phthalimidine fragment was designed and synthesized. Their antiaggregative activity determined by Born's method was shown to be due to inhibition of fibrinogen binding to αIIbβ3. Molecular docking of RGD mimetics to αIIbβ3 receptor showed the key interactions in this complex, and also some correlations have been observed between values of biological activity and docking scores. The single crystal X-ray data were obtained for five mimetics.